Atrium TherapeuticsRNA +3.21%12 PS Ratio is 10.98 as of Jun. 27, 2026, which is 1% below its 10-year median of 11.13. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 936 Biotechnology companies, Atrium Therapeutics ranks worse than 53.63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Atrium Therapeutics's share price is $13.15.
Atrium Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.20. Hence, Atrium Therapeutics's PS Ratio for today is 10.98.
The historical rank and industry rank for Atrium Therapeutics's PS Ratio or its related term are showing as below:
RNA'
s PS Ratio Range Over the Past 10 Years
Min: 9.85 Med: 11.13 Max: 104.37
Current: 10.98
During the past 3 years, Atrium Therapeutics's highest PS Ratio was 104.37. The lowest was 9.85. And the median was 11.13.
RNA's PS Ratio is ranked worse than 53.63% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs RNA: 10.98
Atrium Therapeutics (NAS:RNA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Atrium Therapeutics PS Ratio Related Terms
Atrium Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atrium Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Atrium Therapeutics's Share Price of today is $13.15. Atrium Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Atrium Therapeutics (RNA) has a PS Ratio of 10.98 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Atrium Therapeutics and its competitors. This is near median its historical median of 11.13. Over the past decade, Atrium Therapeutics' PS Ratio has ranged from 9.85 to 104.37. According to the industry distribution chart, Atrium Therapeutics ranks #502 out of 936 companies in the Biotechnology industry, placing it in the top 53.6%.
Is Atrium Therapeutics' PS Ratio too high?
Atrium Therapeutics' current PS Ratio of 10.98 is near median its 10-year median of 11.13. Over the past 10 years, this metric has ranged from a low of 9.85 to a high of 104.37. The Biotechnology industry median PS Ratio is 9.17. Atrium Therapeutics' value of 10.98 is 19.8% above this industry median. Based on the distribution chart, Atrium Therapeutics ranks #502 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' PS Ratio compare to RNAC and KROS?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #502 out of 936 companies for PS Ratio. This places Atrium Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.17. Atrium Therapeutics' value of 10.98 is 19.8% above this benchmark. Historically, Atrium Therapeutics' own PS Ratio has ranged from 9.85 to 104.37 over the past decade. While the company's 10-year median is 11.13 vs. the industry median of 9.17, Atrium Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrium Therapeutics's current PS Ratio of 10.98 is 19.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Atrium Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrium Therapeutics's current PS Ratio is 10.98, which is near median its own 10-year median of 11.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current PS Ratio of 10.98. The current PS Ratio is 10.98, which is near median its 10-year median of 11.13 and 19.8% above the Biotechnology industry median of 9.17. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current PS Ratio is 10.98 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 